Neotidin Tablets 150 mg (Ranitidine Hydrochloride)
Ranitidine Hydrochloride
Prescription medication
Gujoo Pharmaceutical Co., Ltd.
MFDS item code 200403062 · Notified 2004.06.30
This product's status changed to Approval withdrawn on 2023.06.02. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Treatment of acid-related disorders (such as ulcers), improvement of gastric mucosal lesions, and prevention of Mendelson's syndrome
This medication is used for the treatment of gastric and duodenal ulcers, Zollinger-Ellison syndrome, and gastroesophageal reflux disease. It also helps prevent Mendelson's syndrome before anesthesia and ulcer prevention after surgery. Additionally, it is effective for gastric and duodenal ulcers caused by the use of nonsteroidal anti-inflammatory drugs (NSAIDs). It aids in the improvement of gastric mucosal lesions such as exacerbations of acute and chronic gastritis, upper gastrointestinal bleeding, erosion, hemorrhage, redness, and swelling. It is used to relieve symptoms of heartburn and acid regurgitation due to excessive stomach acid, thereby improving patients' overall gastric health.
Administer 150 mg of ranitidine per dose orally twice daily, in the morning and at bedtime. 1) Gastric and duodenal ulcers Administer 150 mg of this drug per dose orally twice daily, or 300 mg once daily at bedtime. A higher healing rate may be achieved, particularly in patients with duodenal ulcers, by administering 300 mg per dose twice daily, in the morning and at bedtime. The dosage and administration are the same for ulcers caused by nonsteroidal anti-inflammatory drugs or for combination therapy to prevent gastric and duodenal ulcers during long-term use of nonsteroidal anti-inflammatory drugs. Healing usually occurs within 4 weeks, or within 8 weeks for conditions caused by nonsteroidal anti-inflammatory drugs, although healing may occasionally take longer depending on the patient. For patients with recurrent ulcers who responded well to short-term treatment with this drug, administer 150 mg once daily at bedtime as maintenance therapy. 2) Reflux esophagitis Administer 150 mg of this drug per dose twice daily for 8 weeks, or 300 mg once daily at bedtime. For patients with severe reflux esophagitis, the dose may be increased to 150 mg per dose 4 times daily. 3) Zollinger-Ellison syndrome Start treatment with an initial dose of 150 mg of this drug per dose 3 times daily and increase the dose as needed. For severe disease, up to 6 g daily may be administered as directed by a physician. 4) In cases of upper gastrointestinal bleeding due to peptic ulcers, acute stress ulcers, or acute gastric mucosal lesions, treatment is usually initiated with an injectable formulation. Once oral administration is possible, switch to oral administration and give 150 mg of this drug per dose twice daily. 5) Premedication for anesthesia (prevention of Mendelson's syndrome) Administer 150 mg of this drug 2 hours before induction of anesthesia. It is also preferable to administer 150 mg on the night before surgery. 6) Improvement of gastric mucosal lesions (erosions, bleeding, erythema, edema) in the following conditions: acute gastritis, acute exacerbation of chronic gastritis Administer 150 mg of this drug per dose once daily at bedtime. In patients with severe renal impairment and creatinine clearance of 50 mL/min or less, administer 150 mg once daily at bedtime. Depending on the patient's condition, the dosing interval may be extended to 12 hours or longer. Hemodialysis reduces the blood concentration of the drug; therefore, readjust the dosing schedule immediately after hemodialysis. The dose may be adjusted as appropriate according to age and symptoms.
For patients aged 12 years and older, administer 75 mg of this drug per dose orally twice daily (for oral solution only). For ages 8 〜 18 years, up to 150 mg per dose (2 mg per kg of body weight) may be administered twice daily.
This medication should not be used in patients with a history of allergic reactions to this drug or its components. Administration should also be avoided in patients with a history of acute porphyria, as this drug may induce acute attacks. In patients with impaired renal function, the blood concentration of this medication may increase, so dosage adjustment or prolonging the administration interval may be required. Patients with liver dysfunction should also use this medication with caution. Patients with a history of drug allergies, the elderly, and those taking nonsteroidal anti-inflammatory drugs should regularly monitor their condition. Gastric cancer symptoms can be masked, so patients with gastric ulcers or middle-aged patients with recent changes in dyspeptic symptoms should confirm the absence of malignant diseases before using this medication. For patients with positive Helicobacter pylori in gastric or duodenal ulcers, bacterial eradication therapy should be conducted concurrently. This medication may rarely cause serious allergic reactions or blood abnormalities, liver dysfunction, heart problems, gastrointestinal symptoms, neurological abnormalities, skin rashes, etc., so if any unusual symptoms occur, discontinue use immediately and seek medical attention. Regular monitoring of patients' blood, liver, and kidney functions during treatment is important. In particular, elderly patients or those with chronic lung disease, diabetes, or weakened immunity may have a higher risk of pneumonia. Avoid driving or operating dangerous machinery if dizziness or drowsiness occurs. This medication may interact with other drugs, so inform your doctor or pharmacist if you are taking any other medications. Pregnant women or those who may become pregnant, as well as breastfeeding women, should use this medication cautiously only when necessary. The safety in children has not been adequately confirmed, so caution is needed. Elderly patients may have increased blood concentration due to decreased kidney function, necessitating dosage adjustments. Some tests may yield false-positive results while taking this medication, so this should be considered during testing. Although overdose rarely leads to specific toxic symptoms, appropriate treatment such as vomiting or gastric lavage is necessary, and in some cases, hemodialysis may be required. This medication should be kept out of reach of children and transferring it to another container can negatively affect quality. Prolonged use may affect the eyes, so an eye examination may be necessary. Finally, using this medication may reduce gastric acid secretion, increasing the risk of bacterial proliferation in the gastrointestinal tract.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly closed container to prevent exposure to air and moisture. It is best to keep it in a dry place at room temperature between 1 and 30 degrees Celsius.
White round film-coated tablets
100 tablets (10 tablets/PTP*10)/case, 300 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Ranitidine Hydrochloride
Prescription medication
Gujoo Pharmaceutical Co., Ltd.
Ranitidine Hydrochloride 168mg
Prescription medication
Ildong Pharmaceutical Co., Ltd.
Ranitidine Hydrochloride 168mg
Tablet · Prescription medication
Hana Pharmaceutical Co., Ltd.
Ranitidine Hydrochloride 56mg
Prescription medication
Ildong Pharmaceutical Co., Ltd.
Ranitidine Hydrochloride 336mg
Prescription medication
Ildong Pharmaceutical Co., Ltd.
Ranitidine Hydrochloride 168mg
Tablet · Prescription medication
Hanin Pharmaceutical Co., Ltd.
Ranitidine Hydrochloride 112mg
Solution · Prescription medication
Hanin Pharmaceutical Co., Ltd.
Ranitidine Hydrochloride 56mg
Solution · Prescription medication
Hanin Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.